The most promising leading biopharmaceutical stocks in 2023

The in vitro diagnostics sector rose after the market, with Xinhua Medical (8.232) leading the gains, Anbiping, Jinyu Medical, and Kangwei Century Wait to follow the rise. Below, the editor will bring you the most promising leading biopharmaceutical stocks in 2023. Let’s take a look at them together. I hope it can bring reference.

The most promising leading biopharmaceutical stocks

1. Hengrui Pharmaceutical (600276), the first domestic innovative drug stock. The main product lines include anti-tumor, anesthesia, contrast agents, etc. The company's return on net assets has remained above 23% for many years, and its net profit has maintained a growth rate of more than 20% for many years. The company has very strong R&D capabilities, an excellent management team, and strong sales capabilities.

2. Aier Eye Hospital (300015), the first domestic ophthalmology hospital chain. It mainly provides patients with ophthalmic medical services such as diagnosis and treatment of various eye diseases, as well as medical optometry and glasses. The company's return on net assets has remained around 20% for many years, and its net profit has maintained a growth rate of over 30% for many years.

3. Mindray Medical (300760), the first domestic medical device stock. The main product lines include life and information support, in vitro diagnosis, medical imaging, etc. The company's return on net assets has remained above 25% for many years, and its net profit has maintained a growth rate of more than 25% for many years.

What are the leading stocks of in vitro diagnostics

1. Libang Instruments: leading stocks

In the second quarter of 2022, Libang Instruments’ main business is patient monitoring, Maternal and child health, ECG diagnosis, etc., had revenue of 281 million yuan, 151 million yuan, and 143 million yuan, accounting for 33.38%%, 17.92%%, and 16.95%%.

Libon Instrument released its financial report for the third quarter of 2022, achieving operating income of 384 million yuan, a year-on-year increase of 2.08%, net profit attributable to the parent company of 39.3065 million, a year-on-year decrease of -40.25%; earnings per share was 0.07 yuan.

2. BGI: leading stock

In the second quarter of 2022, BGI’s main business is comprehensive solutions for precision medical testing, basic research on infection prevention and control, and clinical application services , basic research on reproductive health and clinical application services, etc., with revenue of 1.542 billion yuan, 573 million yuan, and 566 million yuan, accounting for 48.76%%, 18.11%%, and 17.91%%.

The financial report shows that in the third quarter of 2022, the company’s operating income was 1.353 billion yuan; net profit attributable to listed shareholders was 141 million yuan; fully diluted net asset income was 1.44%; gross profit margin was 56.73%, and earnings per share 0.35 yuan.

3. Saili Medical: leading stock

In the second quarter of 2022, Saili Medical Company’s main business is IVD business, SPD business, pure sales, etc., with revenue of 521 million yuan, 328 million yuan and 301 million yuan, accounting for 45.3%%, 28.51%%, and 26.19%%.

Seli Medical released its financial report for the third quarter of 2022, achieving operating income of 613 million yuan, a year-on-year increase of -2.48%, net profit attributable to the parent company -6.6945 million, a year-on-year increase of -178.32%; earnings per share was -0.03 Yuan.

What are the listed companies with in vitro diagnostic concept stocks?

1. Mindray Medical (300760): The company is mainly engaged in medical devices. According to after-hours news on February 10, Mindray Medical's stock closed at 324.160 yuan, down 0.87%. Within 7 days, the stock price fell 1.5%, with a total market value of 393.025 billion yuan.

2. Wantai Biological (603392): The company is engaged in the research and development, production and sales of in vitro diagnostic reagents, instruments and vaccines. In the latest after-hours news on February 10, Wantai Biotech's stock price rose 0.52% within 5 days. As of the close at 15:00, the stock fell 0.78% to 129.330 yuan.

3. Fosun Pharmaceutical (600196): The company is mainly engaged in pharmaceutical manufacturing and research and development. As of 15:00, Fosun Pharma rose 0.06%, with the stock price at 33.750 yuan, with 15.0406 million shares traded, a transaction value of 508 million yuan, and a turnover rate of 0.71%. The latest total market value of A shares reached 90.185 billion yuan, and the circulating market value of A shares was 71.473 billion yuan. .

4. New Industry (300832): The company is engaged in R&D, production and sales of a series of fully automatic chemiluminescent immunoassay instruments and supporting reagents. According to after-market news on February 10, New Industries opened at 61.59 yuan. As of the close at 15:00, the stock rose 0.52% to 61.900 yuan, with a total market value of 48.661 billion yuan and a PE of 49.84.

5. Lepu Medical (300003): The company’s main business is medical devices, medicine, medical services and new medical formats. According to after-hours news on February 10, Lepu Medical's stock price rose 3.43% within 7 days, and the latest increase was 1% to 24.170 yuan, with a turnover rate of 1.04%.

6. Shanghai RAAS (002252): The company is mainly engaged in the production and sales of blood products. According to news on February 10, Shanghai RAAS has dropped -8.48% this year, with the latest price at 6.250 yuan, an increase of 1.13%, and a turnover of 264 million yuan.

7. Jinyu Medical (603882): The company is engaged in medical services. According to after-market news on February 10, Jinyu Medical opened at 85.52 yuan and closed at 89.060 yuan, with a transaction volume of 446 million yuan.

8. Renfu Pharmaceutical (600079): The company’s main business is medicine. According to after-hours news on February 10, Renfu Pharmaceutical's latest quotation was 25.380 yuan, down 0.82%. The stock price fell 3.62% within 3 days; the increase this year has increased by 1.1%, and the price-to-earnings ratio is 29.17.

What are the leading stocks in medical testing stocks?

1. Mindray Medical: the domestic leader in medical equipment. Life information and support products, in vitro diagnostic products, and medical imaging products.

2. Yuyue Medical: respiratory oxygen supply, rehabilitation care, surgical instruments, high-value consumables, traditional Chinese medicine diagnostic and treatment equipment, medicinal patches and polymer health accessories.

3. Lepu Medical: a leader in the field of cardiovascular medical devices. Stent delivery system for coronary artery dilation, intravascular eluting stent system, PTCA balloon dilatation catheter, PTCA angiography guide wire.

4. Huahai Biotech: A leader in regenerative medicine in China. The products on the market are bioregenerative materials. Among them, soft tissue repair series products such as oral repair membranes, biofilms, and skin repair membranes have been widely used in stomatology, head and neck surgery, Neurosurgery and many other fields.

5. Chutian Technology: leader in medical equipment (automatic light inspection machines, freeze dryers, drug dispensing systems, etc., medical water equipment field).

Ranking of leading medical device stocks

The report shows that in 2019, Mindray Medical achieved operating income of 16.556 billion yuan, an increase of 20.38% over the same period last year; the total profit was 5.368 billion yuan, a year-on-year increase of 20.38%. An increase of 26.66% over the same period last year; the net profit attributable to shareholders of listed companies was 4.681 billion yuan, an increase of 25.85% over the same period last year; in 2019, the company plans to distribute a cash dividend of 15 yuan (tax included) to all shareholders for every 10 shares.

Specifically, the top spot in the medical equipment category is still Mindray Medical, the “biggest brother” of domestic equipment companies. Mindray Medical’s business line is highly comprehensive, covering life information and support, in vitro diagnosis, and medical imaging. Big area. Benefiting from the continuous release of policy dividends, the continued strong demand for medical devices, the steady increase in the global market share of core products, and the rapid expansion of domestic and international high-end customer base, Mindray Medical, China's largest and the world's leading medical device giant, once again relied on its dazzling The financial report data provides a "stimulus boost" for investors.